AVBP
ArriVent BioPharma, Inc. Common Stock
NASDAQ: AVBP · HEALTHCARE · BIOTECHNOLOGY
$31.09
+3.46% today
Updated 2026-04-30
Market cap
$1.34B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-4.32
Dividend yield
—
52W range
$16 – $32
Volume
0.5M
ArriVent BioPharma, Inc. Common Stock (AVBP) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Gross margin | — | — | — | — | — |
| R&D | $6.43M | $30.43M | $64.88M | $79.00M | $153.35M |
| SG&A | $3.02M | $6.47M | $9.71M | $15.30M | $24.18M |
| Operating income | $-8.70M | $-36.91M | $-74.59M | $-94.31M | $-177.53M |
| Operating margin | — | — | — | — | — |
| EBITDA | $-51.61M | $-36.91M | $-74.59M | $-80.49M | $-177.53M |
| EBITDA margin | — | — | — | — | — |
| EBIT | $-63.20M | $-73.81M | $-74.59M | $-94.31M | — |
| Interest expense | — | — | — | — | — |
| Income tax | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-51.61M | $-36.91M | $-69.33M | $-80.49M | $-166.31M |
| Net income growth (YoY) | — | +28.5% | -87.9% | -16.1% | -106.6% |
| Profit margin | — | — | — | — | — |